Adalimumab
Authors:
- 1 December 2012
- journal article
- Published by Springer Nature in Drugs
- Vol. 72 (18) , 2385-2395
Abstract
Adalimumab is a fully human, recombinant, monoclonal IgGl antibody specific for the cytokine tumour necrosis factor-α. It is approved for the treatment of various inflammatory disorders, including severe non-radiographic axial spondyloarthritis (axSpA). The clinical efficacy of adalimumab (40 mg administered subcutaneously every other week) in adult patients meeting the Assessment of SpondyloArthritis international Society (ASAS) criteria for axSpA but not the modified New York criteria for ankylosing spondylitis (AS) has been demonstrated in the pivotal phase III, randomized, double-blind, placebo-controlled ABILITY-1 trial (n = 192 randomized). In ABILITY-1, adalimumab was effective in improving the signs and symptoms of non-radiographic axSpA in patients who had active disease despite treatment with NSAIDs or who were intolerant to, or had a contraindication for, NSAIDs. Compared with placebo, a significantly greater proportion of patients receiving adalimumab 40 mg every other week achieved an ASAS 40 response after 12 weeks of treatment (primary endpoint). Furthermore, adalimumab significantly decreased inflammation in the spine and sacroiliac joints, as measured by MRI, and improved spondyloarthritic and general measures of health-related quality of life at 12 weeks. Efficacy of adalimumab was sustained over the longer term, according to data at 68 weeks from an open-label extension of ABILITY-1. Adalimumab was generally well tolerated in clinical trials of non-radiographic axSpA; the adverse event profile was similar to that in patients with AS or other approved indications.Keywords
This publication has 20 references indexed in Scilit:
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Annals of the Rheumatic Diseases, 2013
- Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2012
- Referral strategies for early diagnosis of axial spondyloarthritisNature Reviews Rheumatology, 2012
- Alterations in Wnt pathway activity in mouse serum and kidneys during lupus developmentArthritis & Rheumatism, 2010
- Early axial spondyloarthritisCurrent Opinion in Rheumatology, 2010
- The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritisAnnals of the Rheumatic Diseases, 2009
- Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2009
- AdalimumabDrugs, 2006
- Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activationAnnals of the Rheumatic Diseases, 2002
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984